LEIDEN, NETHERLANDS--(Marketwire - June 02, 2010) -
Leiden, The Netherlands, June 2, 2010. Biotech company Pharming Group NV
("Pharming") (NYSE Euronext: PHARM) today announced that its current number of
outstanding shares has increased from 154,501,037 at March 31, 2010 to
277,206,421 as per today.
The increase reflects 100,000,000 shares issued in relation to an equity fundraising of EUR12.0 million ("the Offering") as announced on May 28, 2010, as well as an aggregate number of 22,705,384 shares issued in relation to various conversions of bonds issued in January 2010 and the first quarter interest payment of these bonds. As a result of these conversions, the original nominal value of the bonds issued in January 2010 in the amount of EUR7.5 million has decreased to EUR3.0 million today.
About the Offering On May 27, 2010, Pharming announced its intention to raise EUR12 million by means of a private placement . On May 28, 2010, the details of the Offering, 100 million shares ("the Offer Shares") at an issue price of EUR0.12 per Offer Share, were announced. The price of the Offer Shares was determined based on an extensive period of road shows and marketing research with new institutional investors and existing shareholders. The Offering has initially been pre-offered as a private placement with existing and new institutional investors, leading to pre-commitments for an aggregate amount of EUR5.5 million. Following the approval of a Prospectus, the remainder of the Offering was launched on May 28, 2010 at 8.00 am CET. Non-institutional investors were welcome to participate as well at a minimal investment of EUR50,000. Within two hours, the order book for the Offering was oversubscribed and closed. Subscribing to the Offering is thus no longer possible. Pharming was advised in the Offering by Kempen & Co NV and Petercam Bank NV. Selling agents were Roth Capital, Heartstream Corporate Finance BV, First Berlin and Montrose Capital. All documents relating to the Offering can be found on Pharming's website: www.pharming.com > Investor Relations > Public Reports > Equity Fundraising May 2010.
About Pharming Group NV Pharming Group NV is developing innovative products for the treatment of genetic disorders, ageing diseases, specialty products for surgical indications, and nutritional products. Pharming's lead product Rhucin® for acute attacks of Hereditary Angioedema has passed clinical development stage and the Market Authorization Application is under review with the European Medicines Agency. Prodarsan® - a product under development by Pharming's subsidiary DNage - is in early stage clinical development for Cockayne Syndrome and lactoferrin for use in food products. The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, technology and processes for the purification and formulation of these products, as well as technology in the field of DNA repair (via DNage). Recently the partial spin- out of DNage was initiated. Additional information is available on the Pharming website, http://www.pharming.com.
Contact: Marjolein van Helmond, Pharming Group NV, T: +31 (0)71 52 47 431 or +31 (0)6 109 299 54
[HUG#1421252]
Press release (PDF): http://hugin.info/132866/R/1421252/370585.pdf
Contact:
Marjolein van Helmond
Pharming Group NV
T: +31 (0)71 52 47 431
or
+31 (0)6 109 299 54
